Predictive factors of quality of life in chronic pruritus patients: A cross-sectional study

Choragudi, Siri; Soares, Georgia Biazus; Yosipovitch, Gil

doi:10.1016/j.jdin.2022.12.005

Cited by 7 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PFIC is a category of rare genetic disorders that are defined by impaired bile flow, leading to rapid progression to liver damage and, eventually, liver failure [18][19][20][21]. There are three types of PFIC based on the genetic defect involved: PFIC1, PFIC2, and PFIC3.…”

Section: Table 2: Summary Of Outcomes and Safety Of Odevixibat In Cli...mentioning

confidence: 99%

Odevixibat: A Novel Bile Salt Inhibitor Treatment for Pruritus in Progressive Familial Intrahepatic Cholestasis

Flattmann,

Mohiuddin,

Singh

et al. 2024

Cureus

View full text Add to dashboard Cite

Chronic pruritus is defined as an itch lasting greater than six weeks. It can manifest from a wide variety of etiologies, as many different substances can act as pruritogens, such as steroids, histamine, progesterone, endogenous opioids, and serotonin. In the setting of cholestatic liver disease, increased bile acids play a major role in chronic pruritus. The itching in cholestatic liver disease is worsened in intensity at night and localized frequently to the palms, soles, knees, and other pressure sites. It can be hard to manage, affecting the quality of sleep and causing irritability, poor attention, and, in some cases, depression. One such disease that results from chronic pruritus is progressive familial intrahepatic cholestasis (PFIC), a group of uncommon hereditary disorders that affects the formation of bile and its outflow from the liver. Previously, the drug ursodeoxycholic acid was used to help manage pruritus or surgical procedures, e.g., partial external biliary diversion or partial internal biliary diversion, to help control complications of the disease. This literature review will discuss three clinical studies covering the effectiveness of odevixibat in treating pruritus in patients with PFIC. Odevixibat (Bylvay) is an oral drug that has been FDA-approved to treat pruritus in patients three months of age and older with PFIC. Odevixibat prevents the reabsorption of bile salts in the intestines, resulting in decreased levels of bile salts via their excretion in stool. Several studies have determined that the drug is well tolerated and provides a nonsurgical, pharmacological treatment alternative for those with PFIC.

show abstract

Section: Table 2: Summary Of Outcomes and Safety Of Odevixibat In Cli...mentioning

confidence: 99%

Odevixibat: A Novel Bile Salt Inhibitor Treatment for Pruritus in Progressive Familial Intrahepatic Cholestasis

Flattmann,

Mohiuddin,

Singh

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Besides, its treatment remains a clinical challenge, but a nuclear topic in psychodermatology, considering the significant impact of CP on patients' quality of life. 1 Several molecules have emerged in recent years targeting a wide number of skin disorders associated with CP. However, if the number of scientific publications targeting biologics has significantly grown, the representativeness of publications on psychodermatology in leading dermatology journals, 2 namely about psychodermatological aspects of CP and their management, needs more attention and improvement.…”

mentioning

confidence: 99%

“…5 Pruritus frequently occurs in such dermatoses and alexithymia could be a feature that links them. 1 Future studies should examine the association between CP and alexithymia in non-inflammatory dermatoses and compare it with skin disorders whose pathophysiology would involve psychological stress.…”

mentioning

confidence: 99%

Chronic pruritus and alexithymia

Ferreira

Miséry

2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

Itch improvement has a major and comparable effect on the Dermatology Life Quality Index in psoriasis and atopic dermatitis patients

Boehncke,

Reich,

Ständer

et al. 2024

JEADV Clinical Practice

View full text Add to dashboard Cite

BackgroundItch is known to have a particularly high impact on psoriasis (PsO) and atopic dermatitis (AD) patients' quality of life. Although AD therapies have exhibited a high efficacy when it comes to itch control, itch control with PsO therapies is not as well documented.ObjectivesThe aim of this post‐hoc analysis is to better understand the impact of itch on the patients' quality of life in PsO as well as AD by providing a pairwise correlation between itch improvement and patients' quality of life and determine the predictive factors in patients achieving Dermatology Life Quality Index score of 0 or 1 [DLQI (0/1)].MethodsThree phase III clinical studies, one in PsO and two in AD, were assessed. Pairwise correlations between objective improvement of visible signs of disease, quality of life, and itch intensity were investigated at 16 weeks of treatment. Predictive analyses methods were applied on the data to assess the impact of clinical and itch improvement on the DLQI improvement.ResultsThis study shows that change in itch from baseline in AD and PsO patients correlate to change in DLQI from baseline. Change in itch from baseline was found to be the most important factor in predicting DLQI (0/1).ConclusionsThese results highlight the necessity to study itch in both PsO and AD clinical trials, and it is recommended that itch may be considered a coprimary or at minimum a secondary efficacy end‐point in all such clinical studies.

show abstract

Predictive factors of quality of life in chronic pruritus patients: A cross-sectional study

Cited by 7 publications

References 24 publications

Odevixibat: A Novel Bile Salt Inhibitor Treatment for Pruritus in Progressive Familial Intrahepatic Cholestasis

Odevixibat: A Novel Bile Salt Inhibitor Treatment for Pruritus in Progressive Familial Intrahepatic Cholestasis

Chronic pruritus and alexithymia

Itch improvement has a major and comparable effect on the Dermatology Life Quality Index in psoriasis and atopic dermatitis patients

Contact Info

Product

Resources

About